anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
MAIA Biotechnology · pitchdeck

MAIA Biotechnology | Investor Presentation Deck | 39 slides

39 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

MAIA Biotechnology | Investor Presentation Deck | 39 slides

MAIA Biotechnology · 2023-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 10 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 11 hits
— 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides
— 0/2 slides
Solution 4 slides 100% 4/4 slides 100% 4/4 slides · 15 hits
— 0/4 slides
50% 2/4 slides
— 0/4 slides
100% 4/4 slides 75% 3/4 slides · 4 hits Market Size 2 slides 100% 2/2 slides 100% 2/2 slides · 13 hits
— 0/2 slides
100% 2/2 slides · 4 hits 50% 1/2 slides 100% 2/2 slides
— 0/2 slides
Team 2 slides 100% 2/2 slides 100% 2/2 slides · 14 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides
— 0/2 slides

Slide inventory

39
every slide · same image gating as the playbook
01
Slide 1
The background image depicts chromosomes, reinforcing the telomere-targeting focus.front_matter
Open slide detail
02
other
Open slide detail
03
other
Open slide detail
04
The slide outlines the status of THIO-101, 102, and 103 trials and mentions specific patent filings.summarize
Open slide detail
05
The slide uses a Gantt-style layout to map drug candidates against clinical development stages.plan_implementation
Open slide detailBeat · Problem
06
The slide uses a chromosome icon for the lead asset and a fast-forward icon for the pipeline strategy.present_solution
Open slide detailBeat · Problem
07
transition
Open slide detailBeat · Solution
08
The slide uses a three-column layout with circular callouts to present demographic and health statistics.establish_context
Open slide detailBeat · SolutionLoop · Why Now
09
This slide serves as a transition or key message reinforcement.establish_context
Open slide detailBeat · SolutionLoop · Pattern Hunter
10
The slide uses a visual comparison between telomere targeting (left) and PD-1/PD-L1 checkpoint inhibition (right).present_solution
Open slide detailBeat · SolutionLoop · Pattern Hunter
11
Slide highlights a strategic partnership/supply agreement as a form of business traction.show_traction
Open slide detailLoop · Pattern Hunter
12
The chart shows tumor volume over time, highlighting the efficacy of the THIO + Atezo combination compared to controls.present_solution
Open slide detailLoop · Pattern Hunter
13
The slide outlines a clinical trial process flow including randomization and expansion phases.plan_implementation
Open slide detailLoop · Pattern Hunter
14
The table compares Cyramza+Docetaxel, Docetaxel alone, and THIO+Libtayo.compare_peers
Open slide detailLoop · Pattern Hunter
15
The slide highlights that THIO has a better safety profile than standard chemotherapy, which typically has 70-80% incidence of Grade 3-5 side effects.show_traction
Open slide detail
16
DCR stands for Disease Control Rate. The table compares historical clinical trial data (KEYNOTE 024, REVEL, RWD) against the company's own THIO-101 trial data.compare_peers
Open slide detail
17
Data presented in a table format with specific clinical definitions for DCR and treatment lines.show_traction
Open slide detail
18
DCR = Disease Control Rate. Data presented in three separate tables for different dose cohorts.analyze_data
Open slide detail
19
Clinical trial data visualization showing patient-level outcomes over time.analyze_data
Open slide detail
20
The chart tracks individual patient outcomes over time, including treatment status, response type, and study exit reasons.analyze_data
Open slide detail
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.show_traction
Open slide detail
22
The slide shows a biological mechanism of action (MOA) validation using a dot plot to show TIFs increase over 72 hours.present_solution
Open slide detail
23
The slide outlines a multi-stage clinical trial design (Part A/B to Part C) involving immune activation with various checkpoint inhibitors.plan_implementation
Open slide detail
24
The slide presents two line charts showing tumor volume reduction and long-term survival/rechallenge success.show_traction
Open slide detail
25
The table compares three treatment regimens across four categories: Expected Efficacy, Safety Profile, Administration, and Trial of Reference.compare_peers
Open slide detail
26
The table compares historical standard of care data against planned THIO-102 trial outcomes.compare_peers
Open slide detail
27
compare_peers
Open slide detail
28
The slide presents two line charts showing tumor volume reduction over time for different treatment regimens in SCLC and HCC mouse models.show_traction
Open slide detail
29
The chart shows a clear divergence between the control group (increasing tumor volume) and the THIO group (decreasing tumor volume to near zero).show_traction
Open slide detail
30
The slide shows two line charts representing tumor volume over time in HCC models, highlighting the efficacy of THIO and THIO+Libtayo combinations.show_traction
Open slide detail
31
The slide outlines a clinical trial process flow from initial baskets through immune activation to a pivotal phase.plan_implementation
Open slide detail
32
The slide highlights both regulatory NCE exclusivity and a specific count of issued/pending patents.other
Open slide detail
33
Includes a logo grid at the bottom representing past affiliations.other
Open slide detailBeat · Team
34
Includes details on options, warrants, and insider ownership percentage.analyze_data
Open slide detailBeat · Team
35
transition
Open slide detail
36
The chart compares the $42B combined market of major CPIs against a $0.5B figure, likely representing the company's specific asset or segment.size_opportunity
Open slide detailBeat · Market Size
37
The slide uses a logo-grid and metric-grid to establish valuation context.compare_peers
Open slide detailBeat · Market Size
38
The slide uses a growth curve background to imply value accumulation over time.plan_implementation
Open slide detail
39
The slide serves as a milestone marker for the company's public listing.show_traction
Open slide detail